Registration

GEPHARDT GROUP GOVERNMENT AFFAIRS for TEVA PHARMACEUTICALS USA, INC.

Firm
Client
Income
—
Expenses
—

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

FDA and healthcare policy; international trade agreements

LobbyistCovered position, as disclosed
ROBERT EPPLIN New Analyst, OMB Budget Review Division; LA and LD, Sen. SmithLD, Sen. Collins
RICHARD GEPHARDT New Member of Congress
ANDREA KING New —
MICHAEL MESSMER New Executive Assistant, House Democratic Leader
JANICE O'CONNELL New —
THOMAS O'DONNELL New —

Trade (domestic/foreign) TRD

FDA and healthcare policy; international trade agreements

LobbyistCovered position, as disclosed
ROBERT EPPLIN New Analyst, OMB Budget Review Division; LA and LD, Sen. SmithLD, Sen. Collins
RICHARD GEPHARDT New Member of Congress
ANDREA KING New —
MICHAEL MESSMER New Executive Assistant, House Democratic Leader
JANICE O'CONNELL New —
THOMAS O'DONNELL New —

Copyright/Patent/Trademark CPT

FDA and healthcare policy; international trade agreements

LobbyistCovered position, as disclosed
ROBERT EPPLIN New Analyst, OMB Budget Review Division; LA and LD, Sen. SmithLD, Sen. Collins
RICHARD GEPHARDT New Member of Congress
ANDREA KING New —
MICHAEL MESSMER New Executive Assistant, House Democratic Leader
JANICE O'CONNELL New —
THOMAS O'DONNELL New —

Foreign entities

Foreign owners and affiliates the filer disclosed. Amounts are as declared on this filing.

EntityCountryPrincipal place of businessOwnershipContribution declared
ORVET UK United Kingdom United Kingdom 100.0% —
TEVA PHARMACEUTICAL INDUSTRIES, LTD. Israel Israel 100.0% —
TEVA PHARMACEUTICALS EUROPE BV Netherlands Netherlands 100.0% —

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.